207 related articles for article (PubMed ID: 31516190)
1. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
Sherman SI
Trans Am Clin Climatol Assoc; 2019; 130():255-265. PubMed ID: 31516190
[TBL] [Abstract][Full Text] [Related]
2. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
3. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Dadu R; Cabanillas ME
Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
[TBL] [Abstract][Full Text] [Related]
4. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].
Malouf G; Baudin E; Soria JC; Schlumberger M
Bull Cancer; 2009 Jan; 96(1):95-101. PubMed ID: 19211364
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
6. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Lubitz CC; Sadow PM; Daniels GH; Wirth LJ
Thyroid; 2021 Oct; 31(10):1451-1462. PubMed ID: 33860688
[No Abstract] [Full Text] [Related]
7. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
8. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
9. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
10. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
11. Multikinase inhibitors in thyroid cancer.
Licitra L; Locati LD
Ann Oncol; 2012 Sep; 23 Suppl 10():x328-33. PubMed ID: 22987985
[No Abstract] [Full Text] [Related]
12. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
13. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Liu M; Chen P; Hu HY; Ou-Yang DJ; Khushbu RA; Tan HL; Huang P; Chang S
J Cancer Res Clin Oncol; 2021 Feb; 147(2):323-337. PubMed ID: 33387037
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
17. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
18. Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach.
Van den Bruel A; Vauterin T; Poorten VV; Decallonne B
Acta Chir Belg; 2007 Jun; 107(3):271-8. PubMed ID: 17685252
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.
Sherman EJ; Dunn LA; Schöder H; Ho AL; Baxi SS; Ghossein RA; Haque SS; Sima C; Tuttle RM; Pfister DG
Cancer; 2019 Sep; 125(17):2984-2990. PubMed ID: 31174237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
